Overview

Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy

Status:
Active, not recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the ability of a largely self-administered geriatric assessment (GA) to predict toxicity in non-Hodgkin Lymphoma (NHL) patients ≥60 years old receiving chemotherapy or chemoimmunotherapy.

Phase:

N/A

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Treatments:

Prednisone
Rituximab